A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LAG DISORDER

Trial Profile

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LAG DISORDER

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders; Jet lag
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 25 May 2017 Planned number of patients changed from 48 to 90.
    • 21 Jan 2017 Status changed from planning to recruiting.
    • 27 Jul 2016 According to a Vanda Pharmaceuticals media release, screening of patients has began for enrollment in this trial and results from this trial are expected in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top